Mastery EAQ Ch. 34

A  Strong contractions

B  Decreased pain

C  Softened cervix

D  Midline fundus

A  Renal failure

B  Ovarian failure

C  Abnormal vaginal bleeding

D  Pulmonary embolism

A  Hirsutism, Dizziness,, Increased diuresis

B  Hirsutism, Bradycardia, Increased diuresis

C  Anxiety, Dizziness, Blurred vision

D  Blurred vision, Bradycardia, Increased diuresis

A  For at least 6 weeks, starting at the end of the antibiotic regimen

B  For at least 1 month after starting the antibiotic

C  During the entire period the patient is taking the antibiotic

D  Until three throat cultures have been negative for the pathogen

A  Methylergonovine

B  Estradiol

C  Alendronate

D  Megestrol

A  Calcium gluconate

B  Atropine

C  Protamine sulfate

D  Epinephrine

A  Decrease the drug dose immediately.

B  Obtain a prescription for terbutaline.

C  Obtain a prescription for indomethacin.

D  Request a prescription to give calcium gluconate.

A  Place the patient on her left side.

B  Instruct the patient to bear down and push.

C  Immediately discontinue intravenous (IV) fluids.

D  Administer phentolamine mesylate.

A  Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B  Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

C  Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

D  Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

A  Uterine atony

B  Pelvic inflammatory disease

C  Hypertension

D  Nausea and vomiting

A  Temperature

B  Uterine contractions

C  Blood glucose

D  Blood pressure

A  Vaginal bleeding at 38 weeks’ gestation

B  Absence of cervical ripening at 42 weeks’ gestation

C  Ineffective contractions in a full-term pregnancy

D  Radiographic confirmation of cephalopelvic disproportion

A  Current tricyclic antidepressant use

B  Low fluid intake

C  Cigarette use

D  Use of herbal supplements

A  Fetal movement, Uterine hyperactivity, Complete blood cell count

B  Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

C  Uterine hyperactivity, Fetal heart rate, Complete blood cell count

D  The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

A  Denosumab

B  Calcitonin

C  Tamoxifen

D  Ibandronate

A  Ask the patient to include soy in her diet.

B  Inform the patient about the benefits and risks of the therapy.

C  Advise the patient to engage in quiet activities.

D  Persuade the patient to start the therapy.

A  “The treatment should be started as soon as possible.”

B  “The treatment is likely to cause endometrial cancer.”

C  “The therapy may cause thromboembolic events.”

D  “You may need to stop smoking during the therapy.”

A  Ritodrine

B  Terbutaline

C  Bed rest and hydration

D  Magnesium sulfate

A  Hypertension

B  Diabetes

C  Anticonvulsant therapy

D  Antibiotic therapy

A  Norethindrone and ethinyl estradiol

B  Cervical cap with spermicidal jelly

C  Medroxyprogesterone

D  Male condom with spermicidal jelly

A  Joint pain

B  Breast cancer

C  Current smoker

D  Allergy to salmon

A  “Replace the bisphosphonate with calcitonin.”

B  “Space the medications 1 to 2 hours apart.”

C  “Discontinue the calcium supplement.”

D  “Obtain a prescription for increasing the bisphosphonate dose.”

A  “Have a yearly mammogram.”

B  “Report missed menstrual periods.”

C  “Perform weight-bearing exercise.”

D  “Have tests for serum cholesterol.”

A  “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”

B  “Estrogen levels inhibit the release of follicle-stimulating hormone.”

C  “High progesterone levels inhibit the release of luteinizing hormone.”

D  “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”

A  “I no longer experience hot flashes.”

B  “I am no longer experiencing painful intercourse.”

C  “I have seen a great improvement in my sexual desire.”

D  “I have not experienced any uterine bleeding.”

A  Metformin

B  Ferritin

C  Levothyroxine

D  Amoxicillin

A  Stimulates estrogen receptors on the bone to increase bone density

B  Promotes bone absorption of calcium

C  Contains estrogen, which stimulates bone reabsorption

D  Inhibits osteoclast-mediated bone reabsorption

A  Multivitamin, Atenolol

B  Warfarin, Cholestyramine

C  Atenolol, Levothyroxine

D  Levothyroxine, Multivitamin

A  “This medication will help relieve the bone pain I have from my osteoporosis.”

B  “I need to decrease my intake of dairy products to prevent hypercalcemia.”

C  “I need to take this medication with food to prevent damage to my esophagus.”

D  “I will take the medication on an empty stomach and not lie down for 30 minutes.”

A  Hot flashes, Vertigo, Loss of appetite

B  Vertigo, Joint pain, Chest pain

C  Chest pain, Hot flashes, Loss of appetite

D  Hot flashes, Loss of appetite, Joint pain

A  To treat pelvic inflammatory disease

B  To induce cervical ripening

C  To treat gestational hypertension

D  To terminate pregnancy

A  Sedentary lifestyle

B  Smoking heavily every day

C  Increased body mass index (BMI)

D  Consumption of saturated fats

A  Estradiol with progestin increases the risk of endometrial cancer.

B  Estrogen monotherapy increases the risk of breast cancer.

C  Monotherapy with a progestin increases breast cancer risk.

D  Unopposed estrogen increases the risk of endometrial cancer.

A  Prostaglandin E

B  Clomiphene

C  Terbutaline

D  Oxytocin

A  Medroxyprogesterone

B  Estropipate

C  Estrone

D  Megestrol

A  Brown discoloration of face

B  Yellow undertone to the skin

C  Hot flashes

D  Loss of hair

A  Suggest the patient take aluminum hydroxide with the medication.

B  Administer acetaminophen as needed.

C  Monitor the patient’s blood pressure frequently.

D  Assess pulse oximetry continuously.

A  Dinoprostone

B  Clomiphene

C  Indomethacin

D  Oxytocin

A  Ethinyl estradiol

B  Progesterone

C  Choriogonadotropin alfa

D  Clomiphene

A  Weight loss

B  Dysmenorrhea

C  Uterine bleeding

D  Deep vein thrombosis

A  “Endometrial cancer risk can be reduced by adding progestin.”

B  “Vaginal cancer is prevented by adding progestin to the regimen.”

C  “The progestin in the regimen will help prevent breast cancer.”

D  “The progestin in the regimen will help prevent ovarian cancer.”

A  Diminished endometrial tissue proliferation

B  Interference with the proliferation of the fertilized ovum

C  Elevated progesterone levels inhibiting the release of the luteinizing hormone

D  Inhibition of the release of gonadotropins

A  Adrenocorticotropic hormone

B  Luteinizing hormone

C  Antidiuretic hormone

D  Follicle-stimulating hormone

A  Thrombophlebitis

B  Hypertension

C  Dysmenorrhea

D  Weight gain

A  Higher-pitched voice

B  Nausea

C  Weight loss

D  Dry skin

A  Accelerated labor

B  Termination of pregnancy

C  Premature labor

D  Postpartum hemorrhage

A  Esterified estrogens

B  Medroxyprogesterone

C  Alendronate

D  Megestrol

A  Phase 3

B  Phase 4

C  Phase 1

D  Phase 2

A  Monophasic

B  Extended-cycle

C  Triphasic

D  Biphasic

A  Interstitial cell-stimulating hormone

B  Follicle-stimulating hormone (FSH)

C  Luteotropic hormone

D  Luteinizing hormone (LH)

A  Methylergonovine

B  Megestrol

C  Medroxyprogesterone acetate

D  Indomethacin

A  Oxytocin

B  Terbutaline

C  Magnesium sulfate

D  Methylergonovine

A  Raloxifene

B  Clomiphene

C  Methylergonovine

D  Megestrol

A  Day 7

B  Day 3

C  Day 14

D  Day 21

A  Adrenocorticotropic hormone

B  Follicle-stimulating hormone (FSH)

C  Antidiuretic hormone

D  Luteinizing hormone (LH)

A  The fetal heart rate is stable.

B  The patient is ready for delivery.

C  The contractions can be fatal to the patient.

D  The patient’s blood pressure is stable.

A  Current smoking status

B  Compliance with the fertility drugs

C  Presence of abnormal uterine bleeding

D  Current use of medications for depression

A  Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

C  Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

D  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events